Streetbeat News

Regulatory

TSLA

Tesla's stock has dipped following a cut in EV tax breaks, raising questions about whether it's a good time to buy. The company's shares have faced criticism recently, partly due to low oil prices reducing the appeal of electric vehicles.

Portfolio Pulse from

November 18, 2024 | 1:45 pm

CELU

Celularity Inc. has resolved its compliance issue with Nasdaq, ensuring its continued listing on the Nasdaq Stock Market. The company cured its filing delinquency, leading to the cancellation of a scheduled hearing.

Portfolio Pulse from

November 18, 2024 | 1:45 pm

WAVE

Eco Wave Power Global AB has received the final permit from the U.S. Army Corps of Engineers for its wave energy project at the Port of Los Angeles, marking a significant milestone for the first onshore wave energy installation in the U.S.

Portfolio Pulse from

November 18, 2024 | 1:30 pm

BNO

Helima Croft discusses the potential impact of Chris Wright as Secretary of Energy, expecting less regulation and a rollback of Biden's LNG pause. She highlights the role of shareholder demands in drilling decisions and suggests that stricter U.S. sanctions on Iran could reduce oil exports.

Portfolio Pulse from

November 18, 2024 | 1:30 pm

BHC

Bausch Health Companies Inc. and its subsidiary Salix Pharmaceuticals will present the RED-C Phase 3 Study Design at the AASLD meeting. The study focuses on a new investigational product aimed at addressing complications of cirrhosis, specifically to delay the onset of first overt hepatic encephalopathy hospitalization.

Portfolio Pulse from

November 18, 2024 | 1:15 pm

KBXFF

Kobrea Exploration Corp. has received approval from the Province of Mendoza, Argentina, to conduct mineral exploration at its El Perdido and Elena projects in the Western Malargüe Mining District. This approval includes drilling activities.

Portfolio Pulse from

November 18, 2024 | 1:15 pm

TOYO

TOYO Co., Ltd, a solar solution company, updated its 2024 performance expectations and provided preliminary guidance for 2025. The company projects cell shipments of 1.7-1.8 GW for 2024, slightly below the previous target due to U.S. trade investigations, with an expected net income of $10 million.

Portfolio Pulse from

November 18, 2024 | 1:15 pm

ATNM

Actinium Pharmaceuticals reported its Q3 2024 financial results and highlighted developments in its Antibody Radiation Conjugate programs. Key updates include FDA alignment on a Phase 2/3 trial for Actimab-A, selection of Actimab-A for the myeloMATCH program, and FDA clearance for two Iomab-ACT INDs. The company is seeking a strategic partner for Iomab-B and has appointed Dr. June Almenoff to its Board. Actinium has $78.6 million in cash, expected to fund operations into 2027.

Portfolio Pulse from

November 18, 2024 | 1:15 pm

ALLR

Allarity Therapeutics has reported significant progress in its Phase 2 stenoparib trial, including extended treatment duration for patients. The company has also strengthened its cash position to support a follow-up FDA trial and initiated new revenue-generating activities from its laboratory services.

Portfolio Pulse from

November 18, 2024 | 1:15 pm

INTS

Intensity Therapeutics presented promising Phase 1/2 data for its cancer therapy INT230-6, showing improved survival rates and safety in sarcoma patients. The ongoing Phase 3 trial, INVINCIBLE-3, is recruiting globally.

Portfolio Pulse from

November 18, 2024 | 1:15 pm